Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H27FO |
Molecular Weight | 290.4155 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12C[C@@H](F)C(=O)[C@@]1(C)CC[C@@]3([H])[C@@]2([H])CC=C4CCCC[C@]34C
InChI
InChIKey=VHZXNQKVFDBFIK-NBBHSKLNSA-N
InChI=1S/C19H27FO/c1-18-9-4-3-5-12(18)6-7-13-14(18)8-10-19(2)15(13)11-16(20)17(19)21/h6,13-16H,3-5,7-11H2,1-2H3/t13-,14+,15+,16-,18+,19+/m1/s1
Fluasterone is a fluorinated derivative of an endogenous steroid hormone androstenolone (dehydroepiandrosterone, DHEA). According to in vivo studies, fluasterone possess endocrinologic effects manifested in increased estrous cycle length and decreased the weights of the uterus, prostate, seminal vesicles, and testes. The mechanism of action of fluasterone is not yet fully elucidated, but most likely involve inhibition of glucose-6-phosphate hydrogenase. Fluasterone was developed by Aeson Therapeutics and was investigated in the late 1990s for the treatment of asthma, cancer, cardiovascular and metabolic disorders. The development of fluasterone for discontinued, probably due to a combination of low potency and insufficient oral bioavailability. Later, the development of fluasterone was continued by the company SteroTherapeutics. In 2018 the FDA has granted an orphan drug designation for fluasterone for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatosis, and hyperglycemia in patients with Cushing’s syndrome.
Approval Year
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
FDA ORPHAN DRUG |
527116
Created by
admin on Fri Dec 15 15:54:42 GMT 2023 , Edited by admin on Fri Dec 15 15:54:42 GMT 2023
|
||
|
NCI_THESAURUS |
C1636
Created by
admin on Fri Dec 15 15:54:42 GMT 2023 , Edited by admin on Fri Dec 15 15:54:42 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
R7M5UGD04G
Created by
admin on Fri Dec 15 15:54:42 GMT 2023 , Edited by admin on Fri Dec 15 15:54:42 GMT 2023
|
PRIMARY | |||
|
112859-71-9
Created by
admin on Fri Dec 15 15:54:42 GMT 2023 , Edited by admin on Fri Dec 15 15:54:42 GMT 2023
|
PRIMARY | |||
|
SUB34022
Created by
admin on Fri Dec 15 15:54:42 GMT 2023 , Edited by admin on Fri Dec 15 15:54:42 GMT 2023
|
PRIMARY | |||
|
DB06250
Created by
admin on Fri Dec 15 15:54:42 GMT 2023 , Edited by admin on Fri Dec 15 15:54:42 GMT 2023
|
PRIMARY | |||
|
DTXSID90920920
Created by
admin on Fri Dec 15 15:54:42 GMT 2023 , Edited by admin on Fri Dec 15 15:54:42 GMT 2023
|
PRIMARY | |||
|
Fluasterone
Created by
admin on Fri Dec 15 15:54:42 GMT 2023 , Edited by admin on Fri Dec 15 15:54:42 GMT 2023
|
PRIMARY | |||
|
100000127841
Created by
admin on Fri Dec 15 15:54:42 GMT 2023 , Edited by admin on Fri Dec 15 15:54:42 GMT 2023
|
PRIMARY | |||
|
C63639
Created by
admin on Fri Dec 15 15:54:42 GMT 2023 , Edited by admin on Fri Dec 15 15:54:42 GMT 2023
|
PRIMARY | |||
|
133967
Created by
admin on Fri Dec 15 15:54:42 GMT 2023 , Edited by admin on Fri Dec 15 15:54:42 GMT 2023
|
PRIMARY |
SUBSTANCE RECORD